Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death

Modern Pathology

Volumn 29, Issue 1, 2016, Pages 34-42

  Ho, Thai H ^a,b   Kapur, Payal ^c,d   Joseph, Richard W ^e   Serie, Daniel J ^e   Eckel Passow, Jeanette E ^b   Tong, Pan ^f   Wang, Jing ^f   Castle, Erik P ^g   Stanton, Melissa L ^a   Cheville, John C ^b   Jonasch, Eric ^f   Brugarolas, James ^c,d   Parker, Alexander S ^e  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g MAYO CLINIC HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HISTONE H3; HISTONE H3 LYSINE 36; MESSENGER RNA; UNCLASSIFIED DRUG; HISTONE;

AGE; ANIMAL EXPERIMENT; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GENETIC ASSOCIATION; HISTONE METHYLATION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; DISEASE FREE SURVIVAL; DNA METHYLATION; KIDNEY TUMOR; METABOLISM; MORTALITY; MUTATION; PATHOLOGY; RISK FACTOR; SURVIVAL RATE;

CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DNA METHYLATION; HISTONES; HUMANS; KIDNEY NEOPLASMS; MUTATION; RISK FACTORS; SURVIVAL RATE;

EID: 84952719241     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.123     Document Type: Article

References (24)

1. Creighton CJ, Morgan M, Gunaratne PH et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-49.
2. Kudithipudi S, Jeltsch A. Role of somatic cancer mutations in human protein lysine methyltransferases. Biochim Biophys Acta 2014;1846:366-379.
3. Hu M, Sun XJ, Zhang YL et al. Histone H3 lysine 36 methyltransferase Hypb/Setd2 is required for embryonic vascular remodeling. Proc Natl Acad Sci USA 2010;107:2956-2961.
4. Mar BG, Bullinger LB, McLean KM et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun 2014;5:3469-3475.
5. Fontebasso AM, Schwartzentruber J, Khuong-Quang DA et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric highgrade gliomas. Acta Neuropathol 2013;125:659-669.
6. Simon JM, Hacker KE, Singh D et al. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res 2013;24:241-250.
7. Ho TH, Park IY, Zhao H et al. High-resolution profiling of histone H3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene 2015; doi:10. 1038/ onc. 2015. 221.
8. Zigeuner R, Hutterer G, Chromecki T et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol 2010;57:102-109.
9. Frank I, Blute ML, Cheville JC et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168:2395-2400.
10. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012;44:751-759.
11. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
12. Kapur P, Pena-Llopis S, Christie A et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013;14: 159-167.
13. Joseph RW, Kapur P, Serie DJ et al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer 2013;120:1059-1067.
14. Hakimi AA, Mano R, Ciriello G et al. Impact of recurrent copy number alterations and cancer gene mutations on the predictive accuracy of prognostic models in clear cell renal cell carcinoma. J Urol 2014;192:24-29.
15. Behjati S, Tarpey PS, Presneau N et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 2013;45: 1479-1482.
16. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366: 883-892.
17. Vermeulen M, Eberl HC, Matarese F et al. Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers. Cell 2010;142:967-980.
18. Li F, Mao G, Tong D et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell 2013;153:590-600.
19. Luco RF, Pan Q, Tominaga K et al. Regulation of alternative splicing by histone modifications. Science 2010;327:996-1000.
20. Bjerke L, Mackay A, Nandhabalan M et al. Histone H3. 3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov 2013;3: 512-519.
21. Sankin A, Hakimi AA, Mikkilineni N et al. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med 2014;3:1485-1492.
22. Gerlinger M, Horswell S, Larkin J et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014;46:225-233.
23. Joseph RW, Kapur P, Serie DJ et al. Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression. J Urol 2015; doi:10. 1016/j. juro. 2015. 07. 113.
24. Pena-Llopis S, Christie A, Xie XJ et al. Cooperation and antagonism among cancer genes: the renal cancer paradigm. Cancer Res 2013;73:4173-4179.